First Time Loading...

BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 30.1 USD 0.43%
Updated: May 16, 2024

BridgeBio Pharma Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BridgeBio Pharma Inc
Cost of Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
BridgeBio Pharma Inc
NASDAQ:BBIO
Cost of Revenue
-$2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-6%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.6B
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$9.9B
CAGR 3-Years
-17%
CAGR 5-Years
-19%
CAGR 10-Years
-10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.3B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
-14%
CAGR 5-Years
-30%
CAGR 10-Years
-27%

See Also

What is BridgeBio Pharma Inc's Cost of Revenue?
Cost of Revenue
-2.4m USD

Based on the financial report for Mar 31, 2024, BridgeBio Pharma Inc's Cost of Revenue amounts to -2.4m USD.

What is BridgeBio Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
13%

Over the last year, the Cost of Revenue growth was 13%.